» Articles » PMID: 36333236

Epidemiology, Screening, and Prevention of Bladder Cancer

Overview
Journal Eur Urol Oncol
Specialties Oncology
Urology
Date 2022 Nov 4
PMID 36333236
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Bladder cancer (BC) represents a significant health problem due to the potential morbidity and mortality associated with disease burden, which has remained largely unaltered over time.

Objective: To provide an expert collaborative review and describe the incidence, prevalence, and mortality of BC and to evaluate current evidence for BC screening and prevention.

Evidence Acquisition: Data on the estimated incidence and mortality of BC for 2020 in 185 countries were derived from the International Agency for Research on Cancer GLOBOCAN database. A review of English-language articles published over the past 5 yr was conducted using PubMed/MEDLINE to identify risk factors in addition to contemporary evidence on BC screening and prevention.

Evidence Synthesis: BC is the tenth most common cancer worldwide, with 573 278 cases in 2020. BC incidence is approximately fourfold higher in men than women. Tobacco smoking remains the principal risk factor, accounting for approximately 50% of cases. There is insufficient evidence to recommend routine BC screening. However, targeted screening of high-risk individuals (defined according to smoking history or occupational exposure) may reduce BC mortality and should be the focus of prospective randomized trials. In terms of disease prevention, smoking cessation represents the most important intervention, followed by a reduction in exposure to occupational and environmental carcinogens.

Conclusions: BC confers a significant disease burden. An understanding of BC epidemiology and risk factors provides an optimal foundation for disease prevention and the care of affected patients.

Patient Summary: Bladder cancer is the tenth most common cancer worldwide and is approximately four times more common among men than among women. The main risk factors are tobacco smoking, followed by exposure to carcinogens in the workplace or the environment. Routine screening is not currently recommended, but may be beneficial in individuals at high risk, such as heavy smokers. Primary prevention is extremely important, and smoking cessation represents the most important action for reducing bladder cancer cases and deaths.

Citing Articles

The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.

Sheng Z, Xu J, Wang M, Xu X, Zhu J, Zeng S BMC Cancer. 2025; 25(1):468.

PMID: 40087655 DOI: 10.1186/s12885-025-13817-6.


Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer.

Wiesen B, Hargis P, Flores H, Kukreja J Front Oncol. 2025; 15:1519428.

PMID: 40061902 PMC: 11885131. DOI: 10.3389/fonc.2025.1519428.


Leveraging Deep Learning in Real-Time Intelligent Bladder Tumor Detection During Cystoscopy: A Diagnostic Study.

Ye Z, Li Y, Sun Y, He C, He G, Ji Z Ann Surg Oncol. 2025; .

PMID: 40050483 DOI: 10.1245/s10434-025-17015-3.


The interplay between angiogenesis-associated genes and molecular, clinical, and immune features in bladder cancer.

Guo X, Yang J, Cao R, Hao G Discov Oncol. 2025; 16(1):265.

PMID: 40042726 PMC: 11883062. DOI: 10.1007/s12672-025-01966-w.


Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021.

Su X, Tao Y, Chen F, Han X, Xue L Sci Rep. 2025; 15(1):7655.

PMID: 40038504 PMC: 11880295. DOI: 10.1038/s41598-025-92033-5.